#14

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.: 2873-US

Peter R. Baum and William C. Fanslow III

Serial No.:

9/778,187

Group Art Unit: 1644

Filing Date:

February 6, 2001

Examiner: J.H. Roark

For:

**MOLECULES DESIGNATED LDCAM** 

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56, §1.97 and §1.98, Applicants hereby disclose publications known to them which may be material to the patentability of this invention. The publications are listed on the attached Form PTO-1449 and copies are enclosed. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

The above-cited references are submitted under § 1.97(b)(3). To Applicants' knowledge, no first Office Action on the merits has been mailed in the subject application. Thus, no fee is believed to be due for the filing of this information disclosure statement. However, should it be determined that a fee is necessary, Applicant authorizes the Commissioner to charge Applicant's deposit account No. 09-0089 in the amount necessary to permit consideration of this Information Disclosure Statement.

Respectfully submitted,

Paul B. Tran

Registration No. 41,565

Immunex Corporation 51 University Street Seattle, WA 98101 Telephone (206) 587-0430

## **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date indicated below

Date: October 22,2002

Signed\_

Elizabeth M. McCarthy